All quiet on the western front!
Wondering if:
- we wait until quarterly end of month for an update on anything
- will we receive an update on the first payment from BARDA? Or for that matter, confirmation of the second payment from Hologic for Phase 2 Tranche 2?
As Dougie indicated in the August webinar, they have no new products to be released for CY2025, so unless new partnerships are established (which to me new established partners now add minimal to revenue options unless someone like Hologic come on board, which seems unlikely) we are reliant on product revenue increases and the ongoing Hologic revenue to keep this ticking over until CLIA waiver comes end of the year.
They did mention about white labelling / licencing Febridx to other providers, so maybe something comes out of that and improves the figures.
Anyone willing to have a guess at the revenues for this quarter?
Add to My Watchlist
What is My Watchlist?
